Christopher Yea - 17 Feb 2023 Form 4/A - Amendment Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Development Officer
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
17 Feb 2023
Transactions value $
$0
Form type
4/A - Amendment
Filing time
22 May 2023, 21:40:11 UTC
Date Of Original Report
23 Feb 2023
Previous filing
19 May 2023
Next filing
21 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -2.43K -8.33% $0.00 26.7K 17 Feb 2023 Common Stock 2.43K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 filed on February 23, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which mis-reported the vesting schedule and the restricted stock unit as a performance restricted stock unit.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 17, 2022, subject to continued service through each vesting date.